Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY

Start Learning

Touch Loading image
CONFERENCE HUB
Start Learning
Efficacy and safety of izokibep: An investigational IL-17A inhibitor
Advancing Liver Care in Europe: Insights from EASL’s Secretary General, Professor Debbie Shawcross
JOURNALS
Start Learning
Bridging Research and Clinical Practice in Hepatology: EASL’s Approach to Liver Disease in Europe
Breakfree-1: Next-Gen CD19 CAR T Shows Promising Immune Reset in Refractory Systemic Sclerosis
JOURNALS
Start Learning
Breakfree-1: Next-Gen CD19 CAR T Shows Promising Immune Reset Potential in Refractory Systemic Sclerosis
RMDs: Experts tell you what to expect in 2025
JOURNALS
Start Learning
RMDs: What to Expect in 2025
Bioinformatics immuno-oncology
JOURNALS
Start Learning
Shaping Immuno-oncology and Precision Medicine through Bioinformatics: Celebrating a pioneer in progress, Hassan Abushukair
touchFEATURE
Start Learning
What is activated PI3Kδ syndrome (APDS)? Clinical features, diagnosis, treatment and management options
Sponsored content
www.touchimmunology.com
JOURNALS
Start Learning
New data support the efficacy and safety of cendakimab in eosinophilic oesophagitis
touchEXPERT BRIEFING
Start Learning
Advances in the treatment of lupus and Sjögren’s disease
Sponsored content
Itolizumab, a humanized anti-CD6 monoclonal antibody, is a new molecule that acts by immunomodulating the CD6 molecule in ulcerative coltitis
JOURNALS
Start Learning
Novel anti-CD6 monoclonal antibody, itolizumab, showcases proof of concept in ulcerative colitis
touchMDT
Start Learning
Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
CE/CME ACCREDITED

to view Favourites, Keep Notes and Track CME Credits

Favourites
Advancing Vasculitis Care and Medical Education: An Interview with Future Leader, Dr Brian Jaros
View
A phase II trial of LEVI-04, a first-in-class, NT-3 inhibitor for the treatment of knee osteoarthritis: Philip Conaghan, WCO-IOF-ESCEO 2025
View
Medics For Rare Disease – New Year, New Strategy
View
Optimizing Tumour Necrosis Factor Inhibitor Therapy in Rheumatoid Arthritis: Embracing Personalized Medicine
View
Novel strategy shows potential to reduce insulin dependence in type 2 diabetes
View
Clinical Phenotyping and Molecular Endotyping in Osteoarthritis – Personalised Approaches to Therapeutics: Ali Mobasheri, WCO-IOF-ESCEO 2025
View
The STENOVA Trial, a First-in-Class, First-in-Indication Study of AGMB-129 in Fibrostenotic Crohn’s Disease: Florian Rieder, DDW 2025
View
New data support the efficacy and safety of cendakimab in eosinophilic oesophagitis
View
Primary biliary cholangitis: Appraising the changing therapeutic landscape
View
Breakfree-1: Next-Gen CD19 CAR T Shows Promising Immune Reset Potential in Refractory Systemic Sclerosis
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup